UVI5008 (48), a derivative of Psammaplin A, could inhibit the DNA methylation of TSG p16INK4a and RARβ2 (García et al., 2011), which showed strong anti-tumor activity with an IC50 from 0.2 to 3.1 μM. Here, CDKN2A is linked to neoplasm.